<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187862</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB-94/10</org_study_id>
    <secondary_id>2010 DR 1136</secondary_id>
    <nct_id>NCT01187862</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes</brief_title>
  <official_title>Single-center, Randomized, Five-way Crossover Study to Investigate Low-dose Combinations of Caffeine, Efavirenz, Losartan, Omeprazole, Metoprolol, Chlorzoxazone and Midazolam (&quot;Basel Cocktail&quot;) for Simultaneous Phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether a cocktail of seven approved drugs (so-called&#xD;
      &quot;Basel cocktail&quot;) can be used for simultaneous phenotyping of CYP1A2, CYP2B6, CYP2C9,&#xD;
      CYP2C19, CYP2D6, CYP2E1 and CYP3A4.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of phenotyping measures of seven drugs used as a cocktail</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Cytochrome</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Basel cocktail</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam</intervention_name>
    <arm_group_label>Basel cocktail</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Male aged between 18 and 45 years&#xD;
&#xD;
          -  No clinically significant findings on the physical examination&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 28 kg/m2&#xD;
&#xD;
          -  Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg,&#xD;
             and heart rate (HR) 45-90 bpm (inclusive)&#xD;
&#xD;
          -  12-lead electrocardiogram (ECG) without clinically relevant abnormalities&#xD;
&#xD;
          -  Hematology and clinical chemistry results not deviating from the normal range to a&#xD;
             clinically relevant extent&#xD;
&#xD;
          -  Negative results from urine drug screen&#xD;
&#xD;
          -  Ability to communicate well with the investigator and to understand and comply with&#xD;
             the requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any excipients of the drug formulations&#xD;
&#xD;
          -  Treatment with another investigational drug within 30 days prior to screening&#xD;
&#xD;
          -  History or clinical evidence of alcoholism or drug abuse within the 3-year period&#xD;
             prior to screening&#xD;
&#xD;
          -  Excessive caffeine consumption, defined as mor than 800 mg per day&#xD;
&#xD;
          -  History or clinical evidence of any disease and/or existence of any surgical or&#xD;
             medical condition, which might interfere with the absorption, distribution, metabolism&#xD;
             or excretion of the study drug&#xD;
&#xD;
          -  Smoking within the last 3 months prior to screening&#xD;
&#xD;
          -  Previous treatment with any prescribed or OTC medications (including herbal medicines&#xD;
             such as St John's Wort) within 2 weeks prior to screening&#xD;
&#xD;
          -  Loss of 250 ml or more of blood within 3 months prior to screening&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity at screening&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Haschke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2010</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Chlorzoxazone</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

